Programmed Death 1 (PD-1) is a member of the CD28/CTLA-4 family of T-cell regulators, expressed as a co-receptor on the surface of activated T-cells, B-cells, and macrophages. New studies have suggested that the PD-1/PD-L1 signaling pathway may be linked to anti-tumor immunity, as PD-L1 has been shown to induce apoptosis of activated T cells or inhibit activity of cytotoxic T cells. In comparison to CD10 and Bcl-6, PD-1 is expressed by fewer B cells and has therefore been considered a more specific and useful diagnostic marker for angioimmunoblastic T-cell lymphoma. Therapies targeted toward the PD-1 receptor have shown remarkable clinical responses in patients with various types of cancer, including non–small-cell lung cancer, melanoma, and renal-cell cancer

Programmed Death 1 (PD-1) is a member of the

CD28/CTLA-4 family of T-cell regulators, expressed as a

co-receptor on the surface of activated T-cells, B-cells, and

macrophages. New studies have suggested that the

PD-1/PD-L1 signaling pathway may be linked to anti-tumor

immunity, as PD-L1 has been shown to induce apoptosis of

activated T-cells or inhibit activity of cytotoxic T-cells. In

comparison to CD10 and bcl-6, PD-1 is expressed by fewer Bcells

and has therefore been considered a more speci­c and

useful diagnostic marker for angioimmunoblastic T-cell

lymphoma. Therapies targeted toward the PD-1 receptor

have shown remarkable clinical responses in patients with

various types of cancer, including non–small cell lung cancer,

melanoma, and renal-cell cancer.